Nutex Health (NUTX) Earnings Analysis
Nutex Health (NUTX) next reports earnings on 2026-08-06, consensus EPS 4.95 USD. Last quarter (2026-04-30) it beat with EPS 6.52 USD vs 3.99 USD est (+63.4%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E 11.70.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NUTX next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 4.95 USD |
| Revenue estimate | 0.22B |
NUTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 6.52 USD | 3.99 USD | +63.4% | Beat |
| 2026-03-05 | 1.61 USD | 5.56 USD | -71% | Miss |
| 2025-11-19 | 7.76 USD | 1.81 USD | +328.7% | Beat |
| 2025-10-22 | -2.95 USD | -1.43333 USD | -105.8% | Miss |
| 2025-03-31 | 11.12 USD | -0.12 USD | +9366.7% | Beat |
| 2024-11-08 | -1.72 USD | -0.24 USD | -616.7% | Miss |
| 2024-08-08 | -0.07 USD | -0.29 USD | +75.9% | Beat |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
NUTX valuation and analyst view
| Trailing P/E | 11.70 |
|---|---|
| Trailing EPS | 14.382 USD |
| Price / book | 3.04 |
| Dividend yield | 0.00% |
| Market cap | 0.94B |
| Analyst consensus | Buy (2 buy / 0 hold / 0 sell) |
| Avg price target | 235 USD |
Related research pages
Frequently asked questions
When is Nutex Health (NUTX)'s next earnings date?
Nutex Health is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 4.95 USD and revenue estimate of 0.22B.
Did NUTX beat earnings last quarter?
In its 2026-04-30 report, NUTX posted EPS of 6.52 USD versus a 3.99 USD estimate — a beat of 63.4%.
What is NUTX's earnings track record?
Over the last 7 reported quarters with consensus data, NUTX beat estimates 4 times (57%).
What is NUTX's current P/E ratio and EPS?
NUTX trades at a trailing P/E of 11.70 on trailing EPS of 14.382263581068578 USD.
What do analysts rate NUTX?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 235 USD.